You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):子公司鹽酸氨溴索口服溶液能(100ml:0.3g)獲批上市
格隆匯 05-25 16:52

格隆匯5月25日丨恆瑞醫藥(600276.SH)公佈,近日,江蘇恆瑞醫藥股份有限公司子公司山東盛迪醫藥有限公司收到國家藥品監督管理局核准簽發的《藥品註冊證書》。

鹽酸氨溴索口服溶液能增加呼吸道黏膜漿液腺的分泌和減少粘液腺分泌,從而降低痰液粘度,同時促進肺表面活性物質的分泌,增加支氣管纖毛運動使痰液易於咳出,適用於急、慢性支氣管炎引起的痰液粘稠、咳痰困難。

鹽酸氨溴索由德國BoehringerIngelheim公司開發,目前有片劑、注射劑、口服溶液、吸入溶液等多種劑型在國內外上市。公司鹽酸氨溴索口服溶液10ml:30mg規格於2021年底獲批上市,此次新獲批100ml:0.3g規格。

經查詢,2021年氨溴索相關劑型全球銷售額約為5.08億美元。截至目前,鹽酸氨溴索口服液相關項目累計已投入研發費用約1099萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account